NAD+

DNA Damage Draws Down the Pool

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Poly(ADP-ribose) polymerases respond to DNA damage by building ADP-ribose polymers, using NAD+ as the building block. Extensive or sustained damage can therefore consume a substantial fraction of the cellular pool.

Key facts

Family
Poly(ADP-ribose) polymerases (PARPs)
Trigger
DNA damage, particularly strand breaks
Substrate
NAD+, used as ADP-ribose donor
Product
Poly(ADP-ribose) chains
Consequence
Pool depletion under heavy damage
Review
Thapa 2021 (PMID 33387580)

What PARP does when DNA breaks

It binds the break and begins building branched chains of ADP-ribose on itself and on nearby proteins. Those chains are a recruitment signal: highly charged, immediately visible to repair machinery, and rapidly assembled. It is among the fastest responses a cell mounts to genomic damage.

Where the building material comes from

NAD+. Each ADP-ribose unit added to a chain is taken from an NAD+ molecule, releasing nicotinamide. That makes NAD+ a raw material here rather than a cofactor, and the chains can be long, so the consumption per damage event is not trivial.

Research material referenced

NAD+ 500mg, third-party HPLC tested

Buy NAD+ · £49.99

Why this can deplete the pool

Sustained or extensive DNA damage means sustained PARP activity, and sustained PARP activity means continuous NAD+ consumption. Under severe damage the draw can be large enough to compromise processes elsewhere that also need NAD+, including energy metabolism, so a repair response can create a metabolic problem.

The connection to the other consuming enzymes

Sirtuins consume NAD+ as a co-substrate. CD38 cleaves it extracellularly. PARPs use it as a polymer building block. Three families with unrelated functions all drawing on one pool means competition between them, and it is why NAD+ concentration is a shared resource rather than a private one.

Why PARP is a drug target

Thapa and colleagues reviewed PARP-1 as a target for neurodegenerative disease in Life Sciences in 2021, and PARP inhibitors are established in oncology on a separate rationale. An enzyme sitting at the junction of DNA repair and energy metabolism has several routes to therapeutic interest, which is why it appears in unrelated fields.

What this establishes about NAD+ levels

That they reflect demand as well as supply. A fall in NAD+ can mean less is being made or more is being consumed, and those have different causes and different implications. Measuring the level alone does not distinguish them, which is worth remembering when a decline is reported.

Frequently asked questions

What does PARP use NAD+ for?

As the building block for poly(ADP-ribose) chains, which recruit repair machinery to DNA damage.

Does a low NAD+ level mean less is being made?

Not necessarily. It can mean reduced synthesis or increased consumption, and the level alone does not distinguish them.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More NAD+ articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.